Top

Published in:

01-02-2018 | Original Article

Influence of ROI definition on the heart-to-mediastinum ratio in planar ¹²³I-MIBG imaging

Authors: Christiane Klene, MD, Christiane Jungen, MD, Koichi Okuda, PhD, Yuske Kobayashi, MSc, Annabelle Helberg, BA, Janos Mester, PhD, Christian Meyer, MD, Kenichi Nakajima, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2018

Abstract

Background

Iodine-123-metaiodobenzylguanidine (¹²³I-MIBG) imaging with estimation of the heart-to-mediastinum ratio (HMR) has been established for risk assessment in patients with chronic heart failure. Our aim was to evaluate the effect of different methods of ROI definition on the renderability of HMR to normal or decreased sympathetic innervation.

Methods and Results

The results of three different methods of ROI definition (clinical routine (CLI), simple standardization (STA), and semi-automated (AUT) were compared. Ranges of 95% limits of agreement (LoA) of inter-observer variabilities were 0.28 and 0.13 for STA and AUT, respectively. Considering a HMR of 1.60 as the lower limit of normal, 13 of 32 (41%) for method STA and 5 of 32 (16%) for method AUT of all HMR measurements could not be classified to normal or pathologic. Ranges of 95% LoA of inter-method variabilities were 0.72 for CLI vs AUT, 0.65 for CLI vs STA, and 0.31 for STA vs AUT.

Conclusion

Different methods of ROI definition result in different ranges of the LoA of the measured HMR with relevance for rendering the results to normal or pathological innervation. We could demonstrate that standardized protocols can help keep methodological variabilities limited, narrowing the gray zone of renderability.

Wieland DM, Brown LE, Rogers W, Worthington KC, Wu J, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22-31.PubMed

Soman P, Travin MI, Gerson M, Cullom SJ, Thompson R. I-123 MIBG cardiac imaging. J Nucl Cardiol 2015;22:677-85.CrossRefPubMed

Nakajima K, Nakata T. Cardiac I-123-MIBG Imaging for clinical decision making: 22-year experience in Japan. J Nucl Med 2015;56:11S-9S.CrossRefPubMed

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. JACC 2010;55:2212-21.CrossRefPubMed

Nakajima K, Nakata T, Matsuo S, Jacobson AF. Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Eur Heart J Cardiovasc Imaging 2016; (Advance Pub 2015/12/24).

Travin MI. Cardiac radionuclide imaging to assess patients with heart failure. Semin Nucl Med 2014;44:294-313.CrossRefPubMed

Peix A, Mesquita CT, Paez D, Pereira CC, Felix R, Gutierrez C, et al. Nuclear medicine in the management of patients with heart failure: guidance from an expert panel of the International Atomic Energy Agency (IAEA). Nucl Med Commun 2014;35:818-23.PubMedPubMedCentral

Merlet P, Valette H, Duboisrande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1992;33:471-7.PubMed

Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.CrossRefPubMed

10.

Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schaffers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802-12.CrossRefPubMed

11.

Petretta M, Pellegrino T, Cuocolo A. The ‘gray zone’ for the heart to mediastinum MIBG uptake ratio. J Nucl Cardiol 2014;21:921-4.CrossRefPubMed

12.

Nakajima K, Okuda K, Matsuo S, Agostini D. The time has come to standardize 123I-MIBG heart-to-mediastinum ratios including planar and SPECT methods. Eur J Nucl Med Mol Imaging 2015;43:386-8.CrossRefPubMed

13.

Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 2014;21:970-8.CrossRefPubMedPubMedCentral

14.

Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, et al. Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera–collimator combinations. Eur J Nucl Med Mol Imaging 2009;36:560-6.CrossRefPubMed

15.

Pellegrino T, Petretta M, De Luca S, Paolillo S, Boemio A, Carotenuto R, et al. Observer reproducibility of results from a low-dose I-123-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging 2013;40:1549-57.CrossRefPubMed

16.

van der Veen L, Scholte A, Stokkel M. Mathematical methods to determine quantitative parameters of myocardial 123I-MIBG studies: A review of the literature. Nucl Med Commun 2010;31:617-28.PubMed

17.

Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: Implications for clinical studies. J Nucl Cardiol 2004;11:126-33.

18.

Veltman CE, Boogers MJ, Meinardi JE, Al Younis I, Dibbets-Schneider P, Van der Wall EE, et al. Reproducibility of planar I-123-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging 2012;39:1599-608.CrossRefPubMedPubMedCentral

19.

Jacobson AF, Matsuoka DT. Influence of myocardial region of interest definition on quantitative analysis of planar I-123-mIBG images. Eur J Nucl Med Mol Imaging 2013;40:558-64.CrossRefPubMed

20.

Slomka PJ, Mehta PK, Germano G, Berman DS. Quantification of I-123-meta-iodobenzylguanidine heart-to-mediastinum ratios: Not so simple after all. J Nucl Cardiol 2014;21:979-83.CrossRefPubMed

21.

Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol 2011;18:82-9.CrossRefPubMed

22.

Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;327:307-10.CrossRef

23.

Sardanelli F, Di Leo G. Biostatistics for radiologists. Milan: Springer; 2009. p. 133-4.CrossRef

24.

Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60.CrossRefPubMed

25.

Iskandrian AE, Hage FG, Shaw LJ, Mahmarian JJ, Berman DS. Serial myocardial perfusion imaging defining a significant change and targeting management decisions. JACC 2014;7:79-96.PubMed

26.

Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, et al. Prognostic value of serial cardiac I-123-MIBG Imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008;49:907-14.CrossRefPubMed

27.

Drakos SG, Athanasoulis T, Malliaras KG, Terrovitis JV, Diakos N, Koudoumas D, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC 2010;3:64-70.PubMed

28.

Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circulation 2002;66:537-43.CrossRef

29.

Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using I-123-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging 2014;41:1673-82.CrossRefPubMedPubMedCentral

30.

Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30:188-99.CrossRefPubMedPubMedCentral

31.

Verschure DO, Bongers V, Hagen PJ, Somsen GA, van Eck-Smit BLF, Verberne HJ. Impact of a predefined mediastinal ROI on inter-observer variability of planar I-123-MIBG heart-to-mediastinum ratio. J Nucl Cardiol 2014;21:605-13.PubMed

32.

Sardanelli F, Di Leo G. Biostatistics for radiologists. Milan: Springer; 2009. p. 128.CrossRef

Title: Influence of ROI definition on the heart-to-mediastinum ratio in planar 123I-MIBG imaging
Authors: Christiane Klene, MD
Christiane Jungen, MD
Koichi Okuda, PhD
Yuske Kobayashi, MSc
Annabelle Helberg, BA
Janos Mester, PhD
Christian Meyer, MD
Kenichi Nakajima, MD
Publication date: 01-02-2018
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2018
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-016-0708-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Influence of ROI definition on the heart-to-mediastinum ratio in planar ¹²³I-MIBG imaging

Abstract

Background

Methods and Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model

Multimodality imaging: Bird’s eye view from The European Society of Cardiology Congress 2017, Barcelona, August 26-30, 2017

SPECT: Workhorse of state of the art nuclear cardiology

The future of nuclear cardiac imaging: Reflection and a vision

Proceedings from the 2017 Journal of Nuclear Cardiology board meeting

Measurement of MBF by PET is ready for prime time as an integral part of clinical reports in diagnosis and risk assessment of patients with known or suspected CAD